A new expert consensus calls for a fundamental shift in how hormone replacement therapy (HRT) is offered to breast cancer survivors suffering severe menopausal symptoms. Published in Menopause on 30…
In a groundbreaking move to reduce the emotional toll and diagnostic delays associated with breast cancer detection, the University of Chicago Medicine has introduced BIOPSY NOW, a patient-centered initiative offering…
AstraZeneca and Daiichi Sankyo have announced promising Phase 3 trial results for Datroway, their investigational antibody-drug conjugate (ADC) targeting triple-negative breast cancer (TNBC). The trial demonstrated that Datroway significantly slowed…
When a woman hears the words, “You have cancer,” her world shifts in an instant. The journey ahead—marked by treatment, uncertainty, and emotional upheaval—can feel isolating, even for the strongest…
In a landmark step for personalized cancer care, the National Comprehensive Cancer Network® (NCCN®) has launched the NCCN Guidelines Navigator™—a cutting-edge digital platform that redefines how clinicians access and use…
Neoadjuvant therapy, which involves administering treatment before surgery to shrink tumors, has become a cornerstone in breast cancer management. Yet, despite its promise, current clinical decision-making often relies on a…
A new analysis has uncovered stark differences in the rates of breast anaplastic large cell lymphoma (ALCL), a rare cancer often linked to breast implants, among women of different racial…
Eli Lilly’s breast cancer drug Verzenio (abemaciclib) has achieved a significant milestone, with new study results showing it helps people with a common form of early-stage breast cancer live longer.…
ACKNOWLEDGMENT Patient Worthy is grateful to our partner Elephants & Tea for providing the following article by Gina Jackson. Elephants & Tea‘s mission is to help adolescent and young adult…
Vepdegestrant, an investigational oral selective estrogen receptor degrader (SERD), has reached a critical milestone as the U.S. Food and Drug Administration (FDA) reviews its New Drug Application (NDA) for use…
Novel radioactive medicine may be an inconvenient read for many people, but if you or someone you care about has metastatic breast cancer the words will soon become part of…
Editor’s Note: This is the third and final part of a caregiver story-share. To read part one, click here. For part two, click here. These moments of light, these tiny…
Editor’s Note: This is the second part of an ongoing story. The third and final part will be published Tuesday, June 25th. To read part one, click here. The initial…
Editor's Note: This is the first part of an ongoing story. The second part will be published Tuesday, June 17th. The fluorescent lights of the hospital room hummed, a stark…
"Fate whispers to the warrior, 'You cannot withstand the storm.' The warrior whispers back, ‘I am the storm.” -Jake Remington This is Jaime Gibbons' favorite quote. While going through her…
In recognition of Breast Cancer Awareness Month, we are taking you back to this top episode from last year! Colby and Nia Maya sit down with Jasmine Souers, who is…
Jessica is coming up on six years of breast cancer survivorship. She speaks to the importance of performing self-exams, the myth that "you're too young to have breast cancer," and…
Candice's journey with cancer began in 2013 when she discovered a dimple which led to a stage 2 breast cancer diagnosis. In 2021, her battle intensified as the cancer metastasized.…
The immune system is constantly on the alert for cells that have sustained DNA damage. When a cell divides its DNA molecules are, to varying degrees, usually damaged. Yet researchers…
Rare Community Profiles is a Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families, advocates, scientists, and more.…
One in every eight women will be diagnosed with breast cancer within their lifetime. Yet despite the prevalence, there are still many myths about this diagnosis. For example, some people…
A Phase 1/2 clinical trial sought to evaluate the potential of vepdegestrant as a therapeutic option for heavily pretreated individuals with estrogen receptor-positive (ER+) and HER2 negative (HER2-) advanced…
The FDA has granted IDEAYA Biosciences fast track status for IDE161 as a treatment for HR+, Her2- breast cancer. The therapy is a selective inhibitor of ADP ribose glycohydrolase…
Patient Worthy is expanding its platform for sharing patient stories through the production of short-form videos featuring rare disease patients. Recently, we sat down with Margaret, who lives with metastatic…
We are excited to announce that Patient Worthy's award-winning podcast "Wait, How Do You Spell That? A Rare Disease Podcast" is back in action with a new episode. Colby and…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
